Patents by Inventor Ronald A. Laskey
Ronald A. Laskey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8609351Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: GrantFiled: May 15, 2013Date of Patent: December 17, 2013Assignee: Cancer Research Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman
-
Publication number: 20130273577Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: ApplicationFiled: May 15, 2013Publication date: October 17, 2013Inventors: Ronald A. LASKEY, Gareth H. Williams, Nicholas Coleman
-
Patent number: 8470544Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, esophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: GrantFiled: February 28, 2012Date of Patent: June 25, 2013Assignee: Cancer Research Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman
-
Publication number: 20120178103Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: ApplicationFiled: February 28, 2012Publication date: July 12, 2012Applicant: Cancer Research Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman
-
Patent number: 8148087Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: GrantFiled: November 4, 2008Date of Patent: April 3, 2012Assignee: Cancer Research Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman
-
Publication number: 20100143943Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: ApplicationFiled: November 4, 2008Publication date: June 10, 2010Applicant: Cancer Research Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman
-
Patent number: 7459157Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, esophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of hematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: GrantFiled: March 2, 2006Date of Patent: December 2, 2008Assignee: Cancer Research Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman
-
Publication number: 20070275421Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: ApplicationFiled: March 2, 2006Publication date: November 29, 2007Applicant: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Ronald Laskey, Gareth Williams, Nicholas Coleman
-
Patent number: 7056690Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and precancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: GrantFiled: August 7, 2001Date of Patent: June 6, 2006Assignee: Cancer Research Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman
-
Publication number: 20030143646Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and precancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: ApplicationFiled: August 7, 2001Publication date: July 31, 2003Applicant: Cancer Research Campaign Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman
-
Patent number: 6521405Abstract: The invention relates to improvements in cell-free systems for initiating DNA replication under cell cycle control. The system comprises a synchronous population of G1 nuclei which have been released from G0; and S phase cytosol. In a preferred aspect, a polypeptide is supplied to the system, wherein the polypeptide is Cdc6 and/or at least one MCM protein. The system is suitable for DNA replication assays, for example to test substances which modulate DNA replication.Type: GrantFiled: March 9, 2000Date of Patent: February 18, 2003Assignee: Cancer Research Campaign Technology LimitedInventors: Ronald Laskey, Gareth Haydn Williams, Torsten Krude, Kal Stoeber, Anthony David Mills
-
Patent number: 6303323Abstract: Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.Type: GrantFiled: October 21, 1998Date of Patent: October 16, 2001Assignee: Cancer Research Campaign Technology LimitedInventors: Ronald A. Laskey, Gareth H. Williams, Nicholas Coleman